Search

The ISVM has released its Viruses of Microbes-themed issue in microLife journal! Led by Prof. Martin Loessner and Prof. Alexander Harms, the issue highlights recent discoveries in bacterial immunity mechanisms and the importance of phages i

Armata Pharmaceuticals has completed enrollment of its Phase 2 Tailwind study, which will evaluate efficacy of inhaled AP-PA02 in non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection. Data anticipated in the second

Proteon Pharmaceuticals, JAFRAL, and PTC Phage Technology Center have established a non-profit organization called PhageEU in Brussels. With newly elected members of EU Parliament and European Commission coming into office, PhageEU sees an

Jens Hör (Helmholtz Institute for RNA-based Infection Research, Würzburg, Germany) and colleagues at the Weizmann Institute of Science have discovered that bacteria conjugate ubiquitin-like proteins to interfere with phage assembly. Here’s

Mark Grevsen Martinet (Jena University Hospital/Friedrich-Schiller University, Germany) and colleagues have published a preprint on how temperate Pf-like phages induced in P. aeruginosa biofilms can modulate phage and antibiotic resistance,

Always great to find phage researchers in countries we haven’t had representation from before! Tasnime Abdou Ahmad (American University of Beirut, Lebanon) and colleagues isolated and characterized a novel E. phage, AUBRB02. They discuss po

A bacterial antiphage system made of a ubiquitin-like protein, E1 and E2 conjugating enzymes and a deubiquitinase attaches the ubiquitin-like protein to the phage central tail fibre during infection. Infected cells release tailless particle

It's Phage Picks time! This week we've got the fifth rendition of our new format, where we share the papers we keep bookmarked, and keep coming back to. Hey hey phage phans, It’s time again for our most well-loved post format — Phage Picks

Andreas Brödel (Eligo Biosciences) and colleagues have successfully edited E. coli genes in the mouse gut using engineered phages. They used (non-replicative) phage to deliver a base editor, and achieved >90% modification without adverse ef

Fereshteh Bayat (McMaster University) and colleagues have designed a high-throughput phage screening platform comprised of a portable library of individual shelf-stable, ready-to-use phages, in solid tablets that include a phage + luciferin

Hannelore Longin (KU Leuven, Belgium) and colleagues have reviewed the emerging role of posttranslational modifications during phage-bacteria interactions, highlighting their potential impact on protein behavior and suggesting a comprehensi

Emma Spencer (University of Idaho) and colleagues published a new preprint on phages of honeybee pathogen Paenibacillus larvae. They looked at resistance evolution and how phage resistant isolates developed reduced pathogenicity — and phage

A recent meta-analysis reveals that infections are a major (>50%) cause of non-relapse-associated deaths following CAR-T cell therapy.

Phagos (France) is hiring for various roles, including bioprocess and formulation engineers and lab technicians/assistants to advance phage therapy and research.

Prof. Dick de Ridder's Bioinformatics Group and Prof. Bas Zwaan's Laboratory of Genetics at Wageningen University & Research, Netherlands are seeking a PhD candidate to study the spatiotemporal diversity of phages. This role will combine bi

University of Leicester, UK is hiring a Research Technician to study dental phages and their interactions with oral pathogens.

On Nov 19-20, the International Alliance for Biological Standardization (Amsterdam, Netherlands) is hosting a virtual scientific workshop about the veterinary use of phages, specifically looking at quality, safety and efficacy. Speakers fro

In a recent episode of the PhageCast podcast, Graham Hatfull (University of Pittsburgh) discusses the importance of mycobacteriophages and their potential for phage therapy against M. abscessus.

IPATH is calling for labs to help find Achromobacter phages for an upcoming clinical trial for cystic fibrosis with phage therapy, inviting contributions and further information via email at ipath@health.ucsd.edu.

Cytophage Technologies Ltd. have shared the recording of their first investor call since becoming a public company.